Cargando…
Hepatitis elimination by 2030: Progress and challenges
Globally, over 300 million people are living with viral hepatitis with approximately 1.3 million deaths per year. In 2016, World Health Assembly adopted the Global Health Sector Strategy on viral hepatitis to eliminate hepatitis by 2030. Different World Health Organization member countries are worki...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262254/ https://www.ncbi.nlm.nih.gov/pubmed/30510370 http://dx.doi.org/10.3748/wjg.v24.i44.4959 |
_version_ | 1783375064622694400 |
---|---|
author | Waheed, Yasir Siddiq, Masood Jamil, Zubia Najmi, Muzammil Hasan |
author_facet | Waheed, Yasir Siddiq, Masood Jamil, Zubia Najmi, Muzammil Hasan |
author_sort | Waheed, Yasir |
collection | PubMed |
description | Globally, over 300 million people are living with viral hepatitis with approximately 1.3 million deaths per year. In 2016, World Health Assembly adopted the Global Health Sector Strategy on viral hepatitis to eliminate hepatitis by 2030. Different World Health Organization member countries are working on hepatitis control strategies to achieve hepatitis elimination. So far, only 12 countries are on track to achieve hepatitis elimination targets. The aim of the study was to give an update about the progress and challenges to achieving hepatitis elimination by 2030. According to the latest data, 87% of infants had received the three doses of hepatitis B virus (HBV) vaccination in the first year of their life and 46% of infants had received a timely birth dose of HBV vaccination. There is a strong need to improve blood and injection safety. Rates of hepatitis B and C diagnosis are very low and only 11% of hepatitis B and C cases are diagnosed. There is a dire need to speed up hepatitis diagnosis and find the missing millions of people living with viral hepatitis. Up to 2016, only 3 million hepatitis C cases have been treated. Pricing of hepatitis C virus drugs is also reduced in many countries. The major hurdle to achieve hepatitis elimination is lack of finances to support hepatitis programs. None of the major global donors are committed to invest in the fight against hepatitis. It will be very difficult for the low and middle-income countries to fund their hepatitis control program. Hepatitis elimination needs strong financial and political commitment, support from civil societies, and support from pharmaceutical and medical companies around the globe. |
format | Online Article Text |
id | pubmed-6262254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-62622542018-12-03 Hepatitis elimination by 2030: Progress and challenges Waheed, Yasir Siddiq, Masood Jamil, Zubia Najmi, Muzammil Hasan World J Gastroenterol Editorial Globally, over 300 million people are living with viral hepatitis with approximately 1.3 million deaths per year. In 2016, World Health Assembly adopted the Global Health Sector Strategy on viral hepatitis to eliminate hepatitis by 2030. Different World Health Organization member countries are working on hepatitis control strategies to achieve hepatitis elimination. So far, only 12 countries are on track to achieve hepatitis elimination targets. The aim of the study was to give an update about the progress and challenges to achieving hepatitis elimination by 2030. According to the latest data, 87% of infants had received the three doses of hepatitis B virus (HBV) vaccination in the first year of their life and 46% of infants had received a timely birth dose of HBV vaccination. There is a strong need to improve blood and injection safety. Rates of hepatitis B and C diagnosis are very low and only 11% of hepatitis B and C cases are diagnosed. There is a dire need to speed up hepatitis diagnosis and find the missing millions of people living with viral hepatitis. Up to 2016, only 3 million hepatitis C cases have been treated. Pricing of hepatitis C virus drugs is also reduced in many countries. The major hurdle to achieve hepatitis elimination is lack of finances to support hepatitis programs. None of the major global donors are committed to invest in the fight against hepatitis. It will be very difficult for the low and middle-income countries to fund their hepatitis control program. Hepatitis elimination needs strong financial and political commitment, support from civil societies, and support from pharmaceutical and medical companies around the globe. Baishideng Publishing Group Inc 2018-11-28 2018-11-28 /pmc/articles/PMC6262254/ /pubmed/30510370 http://dx.doi.org/10.3748/wjg.v24.i44.4959 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Editorial Waheed, Yasir Siddiq, Masood Jamil, Zubia Najmi, Muzammil Hasan Hepatitis elimination by 2030: Progress and challenges |
title | Hepatitis elimination by 2030: Progress and challenges |
title_full | Hepatitis elimination by 2030: Progress and challenges |
title_fullStr | Hepatitis elimination by 2030: Progress and challenges |
title_full_unstemmed | Hepatitis elimination by 2030: Progress and challenges |
title_short | Hepatitis elimination by 2030: Progress and challenges |
title_sort | hepatitis elimination by 2030: progress and challenges |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262254/ https://www.ncbi.nlm.nih.gov/pubmed/30510370 http://dx.doi.org/10.3748/wjg.v24.i44.4959 |
work_keys_str_mv | AT waheedyasir hepatitiseliminationby2030progressandchallenges AT siddiqmasood hepatitiseliminationby2030progressandchallenges AT jamilzubia hepatitiseliminationby2030progressandchallenges AT najmimuzammilhasan hepatitiseliminationby2030progressandchallenges |